SSY GROUP (02005.HK): noradrenaline 1ml:2mg wins NMPA approval
- Norepinephrine bitartrate injection 1ml:2mg was approved as a Category 3 chemical drug deemed to have passed consistency evaluation.
- The Group offers four adrenaline-class injections with four self-supplied APIs; domestic annual use is estimated at about 200 million vials.
NewTimeSpace News: On 17 November 2026, SSY Group Limited (stock code: 02005) said it obtained NMPA approval to produce norepinephrine bitartrate injection (1ml:2mg), a Category 3 chemical drug deemed to have passed generic consistency evaluation, mainly for blood pressure control in certain acute hypotensive states.
The 4ml:8mg strength was approved earlier; the smaller strength better suits initial dosing, down-titration and paediatric use. Annual domestic use of adrenaline-class emergency medicines is estimated at about 200 million vials. The Group now offers four such injections and self-supplies the four corresponding APIs. Separately, paracetamol and mannitol injection (50ml and 100ml) won approval for a new indication, relieving moderate to severe postoperative pain in adults with opioid analgesics, adding to its existing antipyretic use; the Group is the first in China approved for both uses.
- SSY GROUP (02005.HK): Stiripentol Suspension Renewed on NRDL
- SSY GROUP (02005.HK): Bevantolol Hydrochloride Cleared as API, the Third Domestic Approval
- SSY GROUP (02005.HK): azithromycin tablets pass evaluation
- SSY GROUP (02005.HK): trustee buys 400,000 shares under restricted share award scheme at average HK$2.6122
- CSPC PHARMA (01093.HK): Phase II Trial in China of SYH2066 for RSV Launched